Cellicure, Inc.

Cellicure, Inc. provides innovative cell-based immunotherapy technologies, customized treatment regimens and real-world solutions for the current unmet therapeutic needs created by cancer, infectious diseases, and chronic inflammatory diseases. Our multiple groundbreaking CAR-NK technology platforms break through the current major challenges and bottlenecks of cell therapy development and industrialization, bringing significant competitive advantages. Partnering with Memorial Sloan Kettering Cancer Center (MSKCC), Cellicure’s innovative T cell engineering technology – the nCAR-T system, significantly enhances T cell infiltration and survival in tumor microenvironment, thus achieving better efficacies in the treatment of both solid tumors and hematological cancers.